Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $55.36

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus recommendation of “Moderate Buy” by the eighteen brokerages that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $54.94.

A number of research analysts have issued reports on the company. William Blair reissued a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. Barclays reduced their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. The Goldman Sachs Group dropped their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Citigroup reduced their target price on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Chardan Capital raised their price target on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday, November 18th.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of large investors have recently bought and sold shares of NTLA. Virtu Financial LLC bought a new stake in shares of Intellia Therapeutics during the third quarter valued at about $417,000. Geode Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after acquiring an additional 49,367 shares during the last quarter. Barclays PLC lifted its stake in Intellia Therapeutics by 17.7% during the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after purchasing an additional 44,022 shares during the last quarter. Two Sigma Advisers LP lifted its position in Intellia Therapeutics by 33.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock worth $21,118,000 after buying an additional 257,700 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its stake in shares of Intellia Therapeutics by 108.8% in the 3rd quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company’s stock valued at $5,982,000 after purchasing an additional 151,661 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock opened at $14.30 on Friday. Intellia Therapeutics has a twelve month low of $12.82 and a twelve month high of $34.87. The firm has a market cap of $1.46 billion, a P/E ratio of -2.63 and a beta of 1.81. The firm’s 50-day simple moving average is $18.12 and its 200-day simple moving average is $21.79.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The company’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.38) earnings per share. On average, equities analysts forecast that Intellia Therapeutics will post -5.13 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.